Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
FDA approves Roche's giredestrant pill for advanced breast cancer
00

FDA approves Roche's giredestrant pill for advanced breast cancer

Nov 17, 2026

The U.S. FDA approved Roche Holding's oral drug giredestrant (Wilserdly) in combination with everolimus on November 16, 2026, for advanced ER-positive, HER2-negative, ESR1-mutated breast cancer. In the phase III evERA trial, giredestrant reduced the risk of disease progression or death by 62%, extending median progression-free survival to 10.0 months. Roche is awaiting decisions for earlier disease stages, where giredestrant could become its top product.

FDA approval and indication

  • ▪The U.S. Food and Drug Administration approved Roche Holding's oral selective estrogen receptor degrader giredestrant, marketed as Wilserdly, in combination with Novartis's everolimus on November 16, 2026
  • ▪The FDA approved giredestrant in combination with everolimus for patients with locally advanced or metastatic ER-positive, HER2-negative, ESR1-mutated breast cancer whose disease recurred or progressed on endocrine therapy
  • ▪Prescribing instructions specify that giredestrant must be administered as an all-oral regimen in combination with everolimus for indicated metastatic breast cancer patients

Efficacy results from evERA trial

  • ▪Treatment with giredestrant and everolimus extended median progression-free survival in ESR1-mutated breast cancer patients to 10.0 months from 5.5 months with standard endocrine therapy
  • ▪In the overall evERA trial population studying advanced breast cancer, patients receiving giredestrant plus everolimus achieved a median progression-free survival of 8.8 months
  • ▪In the phase III evERA trial, giredestrant combined with everolimus reduced the risk of disease progression or death by 62% in patients with ESR1-mutated advanced breast cancer

Safety profile and warnings

  • ▪Common laboratory abnormalities observed during giredestrant plus everolimus treatment included decreased blood cell counts and elevated liver enzymes and creatinine
  • ▪The most common adverse reactions associated with giredestrant plus everolimus include stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis, and nausea
  • ▪Prescribing information for giredestrant contains official warnings and precautions regarding the risks of bradycardia and embryo-fetal toxicity

Expanding treatment to earlier stages

  • ▪Roche Holding is currently awaiting an FDA decision regarding the potential approval of giredestrant for earlier stages of breast cancer
  • ▪An FDA approval of giredestrant for earlier stages of breast cancer would make the medication available to a larger group of patients

3 sources

The Wall Street Journal
Roche Secures First U.S. Approval for New Breast-Cancer Pill
View source article
Endpoints
Roche enters the SERD market with FDA approval in late-stage breast cancer
View source article
MedPage Today
Next-Generation Oral SERD Approved for Breast Cancer
View source article

Story comments

Loading comments…

Related entities

Everolimus

Related Projects

Novartis

Topics

Clinical trialsPrecision medicineFDA drug approvalDrug Policy, Pricing & ApprovalCancer treatmentTargeted cancer therapyCancer and Cancer TreatmentOncologyCancer & Oncology